CagriSema: Next-Gen GLP-1 Weight Loss Drug Guide 2026

Quick answer: What is CagriSema?

CagriSema is an investigational weight loss medication being developed by Novo Nordisk that combines two medications in one: semaglutide (the active ingredient in Wegovy and Ozempic) and cagrilintide (a long-acting amylin analogue). By targeting both the GLP-1 and amylin hormone pathways, CagriSema aims to produce greater weight loss than any currently available GLP-1 medication. Early trial data suggests it may achieve 25% or more total body weight loss — potentially surpassing both Wegovy (15%) and Zepbound (22.5%).

CagriSema is not yet FDA-approved. If you need GLP-1 treatment now, check your eligibility for currently available medications or see our best GLP-1 for weight loss guide.

How CagriSema works

CagriSema combines two complementary mechanisms:

Semaglutide (GLP-1 receptor agonist)

Mimics the GLP-1 hormone, which reduces appetite, slows stomach emptying, and improves blood sugar control. This is the same active ingredient in Wegovy and Ozempic. See our GLP-1 weight loss guide for details on how GLP-1 receptor agonists work.

Cagrilintide (amylin analogue)

Mimics amylin, a hormone co-secreted with insulin by the pancreas. Amylin promotes satiety, slows gastric emptying, and reduces post-meal glucagon secretion. By combining amylin with GLP-1, CagriSema targets two distinct appetite-regulating pathways simultaneously.

CagriSema vs other GLP-1 medications

For more on how these medications compare, see our GLP-1 comparison guide and retatrutide vs tirzepatide comparison.

CagriSema clinical trials

CagriSema is being evaluated in the REDEFINE Phase 3 trial program, which includes:

• REDEFINE-1: Evaluating CagriSema vs semaglutide vs placebo in adults with obesity
• REDEFINE-2: Evaluating CagriSema in patients with type 2 diabetes and obesity
• REDEFINE-3: Long-term cardiovascular outcomes trial

Early Phase 2 results showed that the combination of semaglutide and cagrilintide produced greater weight loss than semaglutide alone, supporting the dual-mechanism approach. Full Phase 3 results are expected to confirm these findings.

Expected timeline

• Phase 3 trials: Ongoing in 2026
• Results expected: Late 2026 to early 2027
• FDA submission: Potentially 2027 (if trials are successful)
• FDA approval: Potentially late 2027 or 2028

Note: These timelines are estimates based on typical drug development timelines. Actual approval may come earlier or later.

What to do while waiting for CagriSema

If you need weight loss treatment now, several FDA-approved GLP-1 medications are available:

• Wegovy (semaglutide) — 15% average weight loss, FDA-approved
• Zepbound (tirzepatide) — 22.5% average weight loss, FDA-approved
• Foundayo (orforglipron) — oral GLP-1 pill, FDA-approved April 2026
• Wegovy pill — oral semaglutide, FDA-approved January 2026

Check your eligibility for currently available GLP-1 medications or compare providers in our best GLP-1 telehealth guide.

The bottom line

CagriSema is one of the most promising GLP-1 medications in development, with the potential to exceed the weight loss results of both Wegovy and Zepbound. However, it's not yet available. If you need treatment now, multiple FDA-approved GLP-1 options are accessible through telehealth from $99/month. When CagriSema is approved, we'll update this guide with pricing, availability, and prescribing information.